Abstract
Immortality of tumour cells is strictly correlated to telomerase activity. Telomerase is overexpressed in about 85% of tumour cells and maintains telomere length contributing to cell immortalisation, whereas in somatic cells telomeres progressively shorten until cell death occurs by apoptosis. Different drugs can promote telomeric G-rich overhangs which fold into quadruplex structures that inhibit telomerase activity. Detailed studies on drug-quadruplex complexes are essential to understand quadruplex recognition and address drug design. This review will discuss the energetic aspects of quadruplex-drug interactions with a particular attention to physico-chemical methodologies.
Keywords: Telomerase, telomeric DNA, G-quadruplex, G-quadruplex-drug interactions, physico-chemical techniques
Current Cancer Drug Targets
Title: Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Volume: 7 Issue: 6
Author(s): B. Pagano and C. Giancola
Affiliation:
Keywords: Telomerase, telomeric DNA, G-quadruplex, G-quadruplex-drug interactions, physico-chemical techniques
Abstract: Immortality of tumour cells is strictly correlated to telomerase activity. Telomerase is overexpressed in about 85% of tumour cells and maintains telomere length contributing to cell immortalisation, whereas in somatic cells telomeres progressively shorten until cell death occurs by apoptosis. Different drugs can promote telomeric G-rich overhangs which fold into quadruplex structures that inhibit telomerase activity. Detailed studies on drug-quadruplex complexes are essential to understand quadruplex recognition and address drug design. This review will discuss the energetic aspects of quadruplex-drug interactions with a particular attention to physico-chemical methodologies.
Export Options
About this article
Cite this article as:
Pagano B. and Giancola C., Energetics of Quadruplex-Drug Recognition in Anticancer Therapy, Current Cancer Drug Targets 2007; 7 (6) . https://dx.doi.org/10.2174/156800907781662257
DOI https://dx.doi.org/10.2174/156800907781662257 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews The Role of Imaging in Computer-Assisted Tumor Surgery of the Sacrum and Pelvis
Current Medical Imaging Subcellular Detection and Localization of the Drug Transporter P-Glycoprotein in Cultured Tumor Cells
Current Protein & Peptide Science Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Muscle-Based Gene Therapy and Tissue Engineering for Cartilage and Bone Healing
Current Genomics From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Broadening Our View of Protective Antibody Responses Against HIV
Current HIV Research Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry RNAi in Clinical Studies
Current Medicinal Chemistry Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design